Disconnect between COX-2 selective inhibition and cardiovascular risk in preclinical models

Yevgeniya E. Koshman,Aimee L. Bielinski,Brandan M. Bird,Jonathon R. Green, Kenneth L. Kowalkowski,Jie Lai-Zhang,Prathap Kumar S. Mahalingaiah,James W. Sawicki,Nari N. Talaty,Amanda W. Wilsey,Mark T. Zafiratos,Terry R. Van Vleet

Journal of Pharmacological and Toxicological Methods（2023）

引用 0|浏览5

暂无评分

摘要

Our data suggest that rofecoxib-related cardiovascular events in humans are not predicted by COX-2 potency or selectivity. In addition, the vascular ring model suggested possible adverse cardiovascular effects by COX-2 inhibitors, although these effects were not seen in vivo studies. These results may also suggest that COX-2 inhibition alone is not responsible for rofecoxib-mediated adverse cardiovascular outcomes.

查看译文

关键词

COX inhibitors,Pre-clinical models,Cardiovascular,Anesthetized dog,Safety pharmacology

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要